Development and validation of the @entity30 perceived XXXX questionnaire.

@entity1 @entity717 @entity73 @entity30
BACKGROUND: No validated instruments have been developed to measure @entity717 in @entity30 ( @entity30 ). The aim of our study was to develop and validate a @entity30 perceived @entity717 questionnaire (CPWDQ). METHODS: Development phase: an initial questionnaire containing 52 items was obtained from @entity1 ' interviews plus additional sources; it was completed by 106 @entity1 and the 16 most significant items were selected using a psychometric method in order to create the CPWDQ. Validation phase: The validation assessed the questionnaire's convergent validity, discriminant validity, test-retest reproducibility, and internal consistency in 108 @entity1 . Spearman rank correlation, t-test, intraclass correlation, and Cronbach's alpha were used for the analysis. RESULTS: Convergent validity was confirmed by good correlations between the CPWDQ and: clinical activity (r = 0.59, P < 0.01), the Short Inflammatory Bowel Disease Questionnaire, IBDQ-9, (r = 0.76, P < 0.001), Euroqol-5D (r = 0.53, P < 0.01), and @entity73 (WPAI_CD) r = 0.66 (P < 0.01). Discriminant validity: CPWQ scores were higher in @entity1 expected to have more severe disability, that is, in @entity1 with active disease (n = 38) 32.3    7.3 versus inactive (n = 70) 22.6    5.9 (P < 0.001), in those requiring previous sick leave 30.7    7.5 (n = 45) versus no sick leave 22.6    6.6 (n = 63) (P < 0.01), and in those requiring hospitalization 32.2    8.6 (n = 18) versus no hospitalization 24.7    7.1 (n = 90) (P < 0.01). Internal consistency was also good (Cronbach's alpha = 0.89). Reproducibility: CPWDQ measures obtained 2 weeks apart showed an excellent intraclass correlation coefficient: 0.89 (95% CI: 0.83-0.93). CONCLUSIONS: The CPWDQ seems to be a valid, reliable tool for measuring subjective @entity717 in @entity30 .
